Heart disease remains the leading cause of death in the United States, with cardiovascular disease accounting for more than 940,000 deaths in 2022, according to the American Heart Association. Annual healthcare costs for cardiovascular conditions are projected to rise from $393 billion in 2020 to $1.4 trillion by 2050. Into this growing crisis steps Cardio Diagnostics Holdings (NASDAQ: CDIO), a Chicago-based precision cardiovascular medicine company that employs artificial intelligence, epigenetics, and genetics to detect coronary heart disease—including forms often missed by standard methods—from a simple blood draw.
What sets Cardio Diagnostics apart is its ability to detect coronary heart disease earlier and with high sensitivity. The company’s approach leverages epigenetic markers and AI algorithms to identify disease risk and presence, offering a non-invasive alternative to traditional diagnostic tools that have limitations. Recent commercial and regulatory milestones have strengthened the company’s position, including progress toward broader clinical adoption.
The scale of the problem is immense. According to the AHA, one person dies every 34 seconds from cardiovascular disease in the U.S., and it remains the leading cause of death across men, women, and most racial and ethnic groups. Cardio Diagnostics aims to address this by providing a test that can be administered in a routine clinical setting, potentially enabling earlier intervention and reducing the economic burden.
Investors should note that forward-looking statements involve risks and uncertainties. For more details, see the company’s filings with the SEC, including the Risk Factors section in its most recent Annual Report on Form 10-K. The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO. Full terms of use and disclaimers are available on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
